Algert Global’s TherapeuticsMD TXMD Stock Holding History

Algert Global’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-509	Closed	-$19K	–	1120
2021 Q3	$19K	Buy	+509	New	+$22.6K	﹤0.01%	1006

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Algert Global's TXMD Position: Q4 2021 in Review

Algert Global sold out of TherapeuticsMD (TXMD) in Q4 2021, closing a stake of 509 shares — an estimated $19K sold.

Algert Global first reported a position in TXMD in Q3 2021 and held it in 1 quarter. The position peaked at $19K in Q3 2021. 131 funds tracked by Wall St. Rank hold TXMD as of Q4 2021.

Algert Global reported no remaining TherapeuticsMD position as of Q4 2021 after selling out during the quarter.
Algert Global sold 509 TherapeuticsMD shares in Q4 2021, an estimated $19K.
Algert Global first reported a position in TherapeuticsMD in Q3 2021 and held it in 1 quarter.
Algert Global's TherapeuticsMD position peaked at $19K in Q3 2021.
131 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2021.

Based on Algert Global's 13F filing for Q4 2021, filed 14 Feb 2022.